Finance

Lists
DMRA:NASDAQ
Damora Therapeutics Inc
$22.56
-0.99%
(-0.23) 1D
Sep 18, 9:56:50 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DMRA...
Open
$22.94
High
$23.42
Low
$22.29
Mkt. cap
1.39B
Avg. vol.
436.76K
Volume
52.19K
52-wk high
$34.89
52-wk low
$16.50
EPS
-$139.34
Beta
1.46
Shares outstanding
61.74M
No. of employees
7
Open
$22.94
High
$23.42
Low
$22.29
Mkt. cap
1.39B
Avg. vol.
436.76K
Volume
52.19K
52-wk high
$34.89
52-wk low
$16.50
EPS
-$139.34
Beta
1.46
Shares outstanding
61.74M
No. of employees
7
News stories
From web sources and news partners
About Damora Therapeutics Inc
CEO-
Employees7
Founded2011
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitedamoratx.com
Analyst ratings
Based on 6 analysts giving stock ratings to DMRA in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for DMRA in the last 3 months.
Highest
Current $22.56
$50.00 (+121.68%)
Average
$44.00 (+95.08%)
Lowest
$40.00 (+77.34%)
Analyst
Recommendation
Action
Price target
Projected
Date
Akash Tewari
Jefferies
Buy
Maintained
$50.00
+121.7%
08/11/2026
David Nierengarten
Wedbush
Buy
Maintained
$40.00
+77.3%
08/11/2026
Brian Abrahams
RBC Capital
Buy
Maintained
$40.00
+77.3%
08/10/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$45.00
+99.5%
08/11/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$45.00
+99.5%
08/11/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
08/10/2026
Bradley Canino
Guggenheim
Buy
Maintained
$40.00
+77.3%
06/15/2026
Andrew Berens
Leerink Partners
Buy
Maintained
$51.00
+126.1%
05/15/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Initiated
$46.00
+103.9%
03/25/2026
Michael Yee
UBS
Buy
Initiated
$45.00
+99.5%
02/17/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
1.42M
23.32M
23.78M
25.54M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.74M
4.07M
7.03M
9.45M
Operating expense
3.16M
27.39M
30.81M
34.99M
Total operating expenses
3.16M
27.39M
30.81M
34.99M
Operating income
-3.16M
-27.39M
-30.81M
-34.99M
Other non operating income
-
-
-
-
EBT including unusual items
-3.13M
-200.69M
-27.74M
-30.92M
EBT excluding unusual items
-3.13M
-26.38M
-27.74M
-30.92M
Income tax expense
-
44.00K
42.00K
255.00K
Effective tax rate
-
-0.02%
-0.15%
-0.82%
Other operating expenses
-
-
-
-
Net income
-3.13M
-200.74M
-27.78M
-31.17M
Net profit margin
-
-
-
-
Earnings per share
-
-
-0.62
-0.39
Interest and investment income
42.00K
1.00M
3.07M
4.06M
Interest expense
-
-
-
-
Net interest expenses
42.00K
1.00M
3.07M
4.06M
Depreciation and amortization charges
-
-
-
-
EBITDA
-3.15M
-27.38M
-30.81M
-34.99M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps